Please assess the completion status of the following clinical trial:

Trial Title: Study of Renal Denervation in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 21-80 years old.~* History of chronic HF (\>6 months) with current NYHA II-III symptoms.~* Left Ventricular Ejection Fraction ≤40% on a clinically indicated echocardiogram obtained within 6 months prior to informed consent.~* Requires daily loop diuretic (≥40mg furosemide per day, or equivalent) to maintain euvolemia (absence of congestive signs including jugular venous distension with Jugular Venous Pressure \> 7cm H20, ≥ moderate (2+) peripheral edema, S3).~* Optimized medical therapy for HF. Patients will be receiving guideline-recommended therapy (per the 2013 ACCF/AHA HF Guidelines) including angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker, beta-blockers, and aldosterone antagonists without changes in heart failure medication regimen (including diuretics) for previous 14 days.~* Systolic blood pressure (BP) ≥110 mmHg at time of informed consent.~* Able to maintain stable medications for 52 weeks.~* Suitable renal artery anatomy for Renal Sympathetic Denervation (RSD) procedure. All of the following criteria must be met, based on the screening renal Doppler ultrasound:~* ≥ 20mm treatable length in each renal artery,~* Diameter in treatable segments must be ≥4mm,~* Lone main renal vessel feeding each kidney.~Exclusion Criteria:~* Unable to comply with protocol or procedures.~* Evidence of orthostatic hypotension or known dysautonomia. Orthostatic hypotension is defined by ≥1 of the following feature(s) within 2-5 minutes of quiet standing:~* ≥ 20 mmHg fall in systolic pressure~* ≥ 10 mmHg fall in diastolic pressure~* Symptoms of cerebral hypoperfusion (e.g. dizziness or lightheadedness, visual blurring or darkening of the visual fields, syncope).~* Evidence of or history of renal artery stenosis, nephrectomy, or renal transplant.~* Significant renal impairment as defined by estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73m2 determined by Modification of Diet in Renal Disease (MDRD) equation.~* Significant proteinuria (\>2g protein/daily protein excretion).~* Body mass index (BMI) \>35 kg/m2.~* Acute coronary syndrome within last 4 weeks as defined by ECG changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest discomfort or angina equivalent).~* Coronary revascularization procedures (percutaneous coronary intervention or cardiac artery bypass graft) and or valve surgery within 30 days of screening or expected procedures within the next 6 months.~* Cardiac resynchronization therapy, with or without implantable cardiac defibrillator within 90 days of screening or expected procedures within the next 6 months.~* Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, active myocarditis, active endocarditis, or complex congenital heart disease.~* Severe advanced HF, with ANY of the following features:~* Current or anticipated use of ventricular assist device within the next 6 months.~* Current or anticipated IV vasoactive drug therapy for HF management within the next 6 months.~* Listed cardiac transplant candidate, with transplantation likely within the next 6 months.~* Known allergic reactions to iodinated radiological contrast media or iodinated antiseptics.~* Greater than moderate mitral or aortic stenosis, and/or severe tricuspid regurgitation.~* Terminal illness (other than HF) with expected survival of less than 1 year.~* Female who is pregnant, nursing, or of childbearing potential not practicing effective birth control.~* Enrollment or planned enrollment in another clinical trial within the next 12 months.~* History of urinary outflow tract obstruction, bladder retention and/ or moderate to severe prostate hypertrophy.~* History of adrenal insufficiency~* History of untreated hypothyroidism~* Patients with non-cardiac dyspnea or fatigue due to frailty, motivational factors, pulmonary disease or orthopedic problems that precludes them from performing 6MWT (Six-Minute WalkTest).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Early Symplicity Renal Denervation (Type: OTHER): Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
- Late Symplicity Renal Denervation (Type: OTHER): Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit

Based on this trial design, predict the completion outcome and termination type (if applicable).